Keywords: sanofi, licenses, kyowa, anti-light, mab, deal, worth
Sanofi licenses Kyowa's anti-LIGHT MAb in deal worth up to $315M
Article | 28 May 2009
French drug major Sanofi-Aventis has licensed the global rights to Kyowa Hakko Kirin's anti-LIGHT fully-human monoclonal antibody, which is presently ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
